Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers
Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210145/ https://www.ncbi.nlm.nih.gov/pubmed/37251081 http://dx.doi.org/10.3389/fmolb.2023.1165781 |
_version_ | 1785047005336174592 |
---|---|
author | Zheng, Yang Zou, Jiayu Sun, Chen Peng, Fu Peng, Cheng |
author_facet | Zheng, Yang Zou, Jiayu Sun, Chen Peng, Fu Peng, Cheng |
author_sort | Zheng, Yang |
collection | PubMed |
description | Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non-small cell lung cancer (NSCLC), and colorectal cancer. Numerous preclinical studies have also revealed the significant antitumor effect of T-DM1 on HER2-positive tumors. With the advancement in research, several clinical trials have been conducted to investigate the antitumor effect of T-DM1. In this review, we briefly introduced the pharmacological effects of T-DM1. We reviewed its preclinical and clinical studies, especially on other HER2-positive cancers, establishing what has been encountered between its preclinical and clinical studies. In clinical studies, we found that T-DM1 has a therapeutic value on other cancers. An insignificant effect was observed on gastric cancer and NSCLC, inconsistent with the preclinical studies. |
format | Online Article Text |
id | pubmed-10210145 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102101452023-05-26 Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers Zheng, Yang Zou, Jiayu Sun, Chen Peng, Fu Peng, Cheng Front Mol Biosci Molecular Biosciences Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non-small cell lung cancer (NSCLC), and colorectal cancer. Numerous preclinical studies have also revealed the significant antitumor effect of T-DM1 on HER2-positive tumors. With the advancement in research, several clinical trials have been conducted to investigate the antitumor effect of T-DM1. In this review, we briefly introduced the pharmacological effects of T-DM1. We reviewed its preclinical and clinical studies, especially on other HER2-positive cancers, establishing what has been encountered between its preclinical and clinical studies. In clinical studies, we found that T-DM1 has a therapeutic value on other cancers. An insignificant effect was observed on gastric cancer and NSCLC, inconsistent with the preclinical studies. Frontiers Media S.A. 2023-05-11 /pmc/articles/PMC10210145/ /pubmed/37251081 http://dx.doi.org/10.3389/fmolb.2023.1165781 Text en Copyright © 2023 Zheng, Zou, Sun, Peng and Peng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Zheng, Yang Zou, Jiayu Sun, Chen Peng, Fu Peng, Cheng Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers |
title | Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers |
title_full | Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers |
title_fullStr | Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers |
title_full_unstemmed | Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers |
title_short | Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers |
title_sort | ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other her2-positive cancers |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210145/ https://www.ncbi.nlm.nih.gov/pubmed/37251081 http://dx.doi.org/10.3389/fmolb.2023.1165781 |
work_keys_str_mv | AT zhengyang adotratuzumabemtansinebeyondbreastcancertherapeuticroleoftargetingotherher2positivecancers AT zoujiayu adotratuzumabemtansinebeyondbreastcancertherapeuticroleoftargetingotherher2positivecancers AT sunchen adotratuzumabemtansinebeyondbreastcancertherapeuticroleoftargetingotherher2positivecancers AT pengfu adotratuzumabemtansinebeyondbreastcancertherapeuticroleoftargetingotherher2positivecancers AT pengcheng adotratuzumabemtansinebeyondbreastcancertherapeuticroleoftargetingotherher2positivecancers |